Blog - QualityStocks

TuesdayMay 24, 2022 12:00 pm

The Flagship CWCBExpo of the New York Cannabis Week to be Held June 2-4; Will Foster Relationships Among Hundreds of Business Leaders from Across the Cannabis Ecosystem

The Cannabis World Congress & Business Exposition (“CWCBExpo”) will be held in New York City between June 2-4, 2022 The conference will feature dozens of expert speakers with expertise in developing brands, increasing efficiencies, and investments Hundreds of exhibitors and leading cannabis businesses will showcase cutting-edge product innovations In 2021, revenue from licensed marijuana of $24.5bn – $27bn in the United States eclipsed Starbucks sales throughout North America The Cannabis World Congress & Business Exposition (“CWCBExpo”) event will be held at New York City’s Javits Convention Center, Hall 3A on June 2-4, 2022. As the flagship event during Cannabis Week, a platform…

TuesdayMay 24, 2022 11:25 am

QualityStocksNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Schedules Conference Call to Discuss Q1 2022 Financial Results, Enters Acquisition Agreement

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, will releases its 2022 first-quarter financial results after market close today, May 24, 2022. In addition, the company will host a Zoom conference call to discuss company financial results and corporate updates on Wednesday, May 25. The Zoom event will begin at 10 a.m. ET. EverGen CEO Chase Edgelow will lead the call. In addition, EverGen signed a definitive agreement to acquire 50% interest in a portfolio of RNG development projects, known as Project Radius and owned by Northeast Renewables LP. The acquisition gives EverGen entry into the…

TuesdayMay 24, 2022 11:15 am

Bit Digital Inc. (NASDAQ: BTBT) Remains Optimistic Despite Recent Cryptocurrency Price Fluctuations

The blockchain technology industry is projected to grow to $450 billion by 2028, up from $3.67 billion in 2020, representing a CAGR of 82.4% The cryptocurrency market, which was valued at $1.5 billion in 2021, is projected to grow to $2.3 billion by 2028, representing a CAGR of 6.9% Bit Digital looks to tap into these two markets through strategic investments and technology The company is confident that the value of cryptocurrency will continue to rise, despite the recent drastic price fluctuations Over the past few weeks, the price of many cryptocurrencies have reduced by more than 50%. Industry experts…

TuesdayMay 24, 2022 10:35 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will be participating at the H.C. Wainwright Global Investment Conference. The event is slated to take place May 23-26, 2022, virtually and in-person in Miami, Florida. A video webcast of Climaco’s presentation is now accessible for viewing on-demand for registered attendees and will be available on the company’s website. Following the event, the webcast replay will be archived for 90 days. In addition, CNSP management will be…

TuesdayMay 24, 2022 10:30 am

Nowigence Inc. SaaS Business Model Positioned in Fast-Growing, Billion-Dollar Space

Gartner predicts that SaaS spending will reach $140 billion this year SaaS spending is increasing a stunning 20% per year Nowigence’s flagship offering — Pluaris — makes it happen through this business model A Gartner report has indicated that Software-as-a-Service (“SaaS”) spending is projected to increase 40% in the coming years, an impressive future especially considering that annual spend has already reached hundreds of billions (https://ibn.fm/Lr8gT). That forecast is good news for Nowigence, a savvy company that solves many of today’s information overload problems with a proprietary AI platform that is available through the SaaS business model. “Just how fast…

TuesdayMay 24, 2022 9:45 am

Lightning Network Gains as More Transactions are Processed; LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Among Companies with Substantial BTC Invested in Network

The Lightning Network is being incorporated by more companies, including the likes of Meta, which is currently striving to develop its own stablecoin offering but is receiving backlash from the government CoinCorner has released the first contactless payment card for the Lightning Network; the card works like Visa and other fiat currency cards but utilizes Bitcoin and the Lightning Network for fast and low fee transactions LQwD has ten nodes on the Lightning Network, each growing in BTC capacity and value – the company anticipates continuing to strive toward scalability of BTC The Bitcoin Lightning Network, a layer 2 payment…

TuesdayMay 24, 2022 9:00 am

FuelPositive Corp.’s (TSX.V: NHHH) (OTCQB: NHHHF) Management Shares 2021 Progress, Discusses 2022 Milestones in a Recent Virtual Annual Generation Meeting

FuelPositive is a technology company focused on developing clean energy solutions such as a green ammonia production system, its flagship product The company recently held its AGM, in which management discussed the milestones achieved in 2021 and the plans for 2022 and beyond According to FuelPositive, the first demonstration unit of its green ammonia production system is on track to be “farm-ready” by late summer 2022, although some issues outside its control may cause a delay in operationalization/commissioning at the farm level Management also updated shareholders on the remote monitoring capability of the system, carbon credits as a result of…

MondayMay 23, 2022 1:47 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Among Most Powerful of Chemotherapy Drugs

CNS Pharmaceuticals’ (NASDAQ: CNSP) novel anthracycline Berubicin, which has been developed to treat diseases with unmet need such as the deadly glioblastoma (“GBM”), appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system. “Berubicin was the drug candidate subject of a small-scale phase 1 clinical trial in 2006 that evaluated its safety, which was notable because one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent 16 years. Nearly half of the trial’s patients experienced a statistically significant improvement in clinical benefit.…

MondayMay 23, 2022 1:38 pm

QualityStocksNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments

Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the companies will explore an innovative technology – ZTI’s Z-pod transdermal technology – to develop a ketamine delivery system for those suffering from dysphagia. “In October 2021, Silo entered into a sponsored research agreement with Columbia University incorporating the work of Dr. Christine Ann Denny. According…

MondayMay 23, 2022 1:00 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners to Help Accelerate Regulatory Pathway of CYB003

Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages over classic psilocybin. MDD impacts over 264 million people worldwide, 1/3 to 1/2 of whom demonstrate an inadequate response to antidepressant drug treatment. Against this backdrop, Cybin focuses on finding solutions for those whose lives are impacted by MDD and other mental and emotional disorders. “The company recently completed in vivo preclinical studies of CYB003. The company plans to file an investigational…

Site Search

Company Search